Home Types of Cancer

Types of Cancer

TRPH-222 Shows High Response and a Favorable Safety Profile in Non-Hodgkin’s Lymphoma

Updated results from its Phase 1 multi-center, open-label, monotherapy study of TRPH-222  (formerly called CAT-02-106) in heavily pre-treated patients...

A Safer Method of Stem Cell Transplantation may Eliminate need for Chemotherapy and Radiation...

For hard-to-treat leukemias, lymphomas, and other hematological malignancies, hematopoietic stem cell transplantation (HSCT) is the gold standard of care....
ESMO 2017 - 3

Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer in Patients Treated...

The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed...

Chinese Regulator Conditionally Approves Disitamab Vedotin in Advanced or Metastatic Gastric Cancer

Disitamab vedotin (爱地希®/Aidixi®; Previously known as RC48; Remegen Biosciences) has been granted conditional marketing approval by the National Medical...

How an ADC with Intracellular Drug Release Properties Demonstrates Specific Cytotoxicity against CD7+ Cells...

T-cell acute lymphoblastic leukemia or T-ALL is a biologically distinct form of leukemia. It's distinct from its B lymphoblastic...

Patritumab Deruxtecan Shows Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated...

New data presented at this year’s annual meeting of the American Society of Clinical Oncology, held online June 4...

HERTHENA-Lung01 Study of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC

A first patient has been dosed in HERTHENA-Lung01, a phase II study evaluating patritumab deruxtecan, a HER3 directed DXd...

What to Expect at SABCS 2020: New Data for HER2 and HER3 Directed DXd...

New research data for trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; Enhertu®; Daiichi Sankyo) and patritumab deruxtecan (U3-1402; HER3-DXd), two DXd antibody-drug...

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27% ORR

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics). This is the conclusion from an analysis...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain Cancer

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the...

X